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Abstract 
This work introduces an in vivo cancer marker in mice from 
the altitude of the well, determined by this cancer. The duration of 
development and the altitude of the cancer well are obtained from 
the synchronization of the mechanics and the kinetics of the 
processes of normal and anomalous transport under tumor mass 
growth. The mechanics and the kinetics of these two transports are 
found from the cancer fugacity. At that, it is assumed that these two 
transports are in a fractal distribution network. The spectrum of this 
network is also obtained from the fugacity of the cancer under 
consideration. The cancer fugacity is defined as a photograph of the 
rate of the scaling exponent under tumor mass growth. 
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1. Introduction 
      The in vivo growth of tumors can be described by a law of 
growth of the tumor mass [6]. The consideration of the tumor mass 
under this law of growth corresponds to the development of cancer 
in a tissue which is a physical soft matter. The classical laws of 
tumor growth are laws of growth of the tumor volume [8]. They 
disregard the tissue in which the cancer develops. That is why the 
law of the in vivo growth of tumors is a more adequate 
representation of the actual development of tumors. 
      We shall assume that the tumor is a well of the energy needed 
for its in vivo growth. Here the well of energy will be understood in 
accordance with Aubin and Lesne [1] as duration in time and as 
altitude. 
      The aim of this work is to find a marker of the in vivo cancer in 
mice from the altitude of the well, determined by this cancer. 
 
2. Fugacity of the in vivo Cancer 
      The in vivo growth of tumors can be described [6] by West's 
universal law of growth 
 dm/dt = vmp(t) (1-m/M)1-p(t))          (1) 
      In (1) m is the actual mass, dm/dt is the rate of growth, M is the 
asymptotic value of m(t), v characterizes the cell-line metabolic rate, 
p(t) is the scaling exponent of growth. 
      The scaling exponent p(t) is obtained in [6] for three lines of 
tumor cells. It has been found out that, in these cases, the scaling 
exponent first decreases, and then increases. It has been suggested 
[6] that this behavior of the scaling exponent is due to the change of 
the tumor's dominating nutrient-supply mechanism from passive 
diffusion to active perfusion (angiogenesis). The decreasing scaling 
exponent will be denoted by p1(t), and the increasing one - by p2(t). 
      The scaling exponent rates a and b are obtained from the data 
taken from the three figures in [6], under the following regression 
between them and time 
 p1(t) ~ exp (at + c)           (2) 
 p2(t) ~ exp (bt + d) 
      The values of (a, b) for the three cell lines are 
 (a1, b1) = (4.5143*10-³, -1.8692*10-²)         (3) 
 (a2, b2) = (-6.0405*10-², 7.4514*10-³) 
 (a3, b3) = (-6.1118*10-³, 1.0844*10-³) 
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      The scaling exponent rate will be replaced by its photograph. 
The photographic scaling down is ten times in space, and it is kπ, k - 
an integer, in time [5]. 
      The photograph of the scaling exponent rate, α, under diffusion, 
is obtained from a and b, and it is 
 α1 = a110³/π, α2 = b210³/2π, α3 = -a310³/π        (4) 
      The photograph of the scaling exponent rate, β, under perfusion, 
is obtained from a and b, and it is 
 β1 = -b110²/π, β2 = -a210²/4π, β3 = -b310³/π        (5) 
      The photographed rates of the scaling exponent show the 
fugacity of the in vivo cancer development. 
      DEFINITION 1. The fugacities of the in vivo cancer develop-
ment in mice are the photographed rates (4), (5) of the scaling 
exponent p(t). 
 
3. In vivo Cancer Marker 
      Let the photographed rates of the scaling exponent set the 
spectrum of the fractal distribution network from [6]. The spectrum 
of these fractals has an angular speed θ [7] 
 θ = (((2+α)² - 4α(1-cos(2πβ)/2))/(4α))½        (6) 
      The in vivo cancer development will be regarded as a system 
with normal and anomalous transport in the fractal distribution 
network. The predominant transport in the fractal distribution 
network will be considered to be normal under passive diffusion, 
and anomalous - under active perfusion. 
      The mechanics of this system with normal and anomalous 
transport gives the moment of termination of the conflict between 
these two processes. 
      The kinetics of this system with normal and anomalous transport 
gives the moment of domination of the anomalous transport. 
      The coincidence of the two moments is synchronization of the 
mechanics and kinetics of the above system with transport. Let the 
common moment of the mechanics and kinetics be denoted by t*. 
      We shall assume that this moment t* is the critical moment at 
which the spectral expansion of a non-self-adjoint harmonic 
oscillator is norm convergent for t>t* and divergent for 0≤t<t*. 
      From (6) and from the results in [3] it follows that 
 t* ~ exp(tg(θ*))/2,  θ* = πθ/2  or  θ* = 3θ/2        (7) 
      The values of t* for the three cell lines are 
 t1* = 10.97,  t2* = 11.24,  t3* = 12.88         (8) 
 4
      In (8) t1* and t2* are obtained for θ* = πθ/2 in (7), and t3* is 
obtained for θ* = 3θ/2 in (7). 
      The conflict between the normal and the anomalous transport is 
a game of pursuit. The terminal closeness of the two processes is [2] 
 ε = (Г(α)/Г(β))(β/α-β) / Г(β+1) − (Г(α)/Г(β))(1-β) / Г(α+1)    (9) 
      In (9) Г(·) is the gamma function. 
      The values of ε for the three cell lines are 
 ε1 = 0.5974,  ε2 = 0.5511,  ε3 = 1.0417         (10) 
      The mean of the diffusion for the one dimensional space kinetics 
of a system with normal and anomalous transport, under domination 
of the anomalous transport, is [9] 
 mk ~ (2/π)((t*/2) ½ Г (1-1/α) +           (11) 
                     (t*/2)(1-1/(2-β)) Г (1+1/(2-β)) + ε) 
      The mean mk from (11) characterizes the anomalous transport 
under in vivo cancer. That is why mk from (11) sets the following 
cost of in vivo cancer dissemination 
 c = mk/2  or  c = mk/2 − 10           (12) 
      The values of c for the three cell lines are 
 c1 = 3.73,  c2 = -1.2,  c3 = 2.44          (13) 
      In (13) c1 and c3 are obtained from (12) for c = mk/2, and c2 is 
obtained from (12) for c = mk/2 − 10. 
      DEFINITION 2. The in vivo cancer in mice sets a well of energy 
with duration t* and altitude c. 
      The three wells of energy, for the three cell lines, are the 
following pairs w 
 w1 = (t1*, c1), w2 = (t2*, c2), w3 = (t3*, c3)         (14) 
      The zeros of the weight system of the colored Jones function for 
the "Figure Eight" knot are [4] 
 λ1 = 1.45,  λ2 = -2.00,  λ3 = -3.45          (15) 
      The values of c from (13) are close to these zeros. The in vivo 
cancer marker will be defined through this correspondence. 
      DEFINITION 3. The in vivo cancer marker in mice, m*, is 
 m* = [c/2] + 2             (16) 
      Here [·] is a rounding of (·). 
      The marker m* has the following values 
                   ⎧4, for the first cell line           (17) 
 m = ⎨1, for the second cell line 
                   ⎩3, for the third cell line 
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4. Conclusion 
      The main result of this work is the defined in vivo cancer marker 
in mice. For this purpose the following have been obtained: 
1) the cancer fugacity; 
2) the duration of the cancer development; 
3) the altitude of the cancer well of energy. 
      The marker has been introduced from the altitude of the cancer 
well of energy. 
      Whether the above marker is valid for all cell lines of in vivo 
cancer in mice will be the subject of investigation in a next work. 
Also in a next work, a check will be made of the validity of the 
proposed in vivo cancer marker in humans. 
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